Relling Mary V, Ramsey Laura B
1St Jude Children's Research Hospital, Memphis, TN.
Hematology Am Soc Hematol Educ Program. 2013;2013:126-30. doi: 10.1182/asheducation-2013.1.126.
Childhood acute lymphoblastic leukemia (ALL) provides an outstanding model for pharmacogenomic research: it is a drug-responsive disseminated cancer that is cured with medications alone in ∼ 85% of patients, but relapse remains unacceptably high for some subgroups. Inherited genomic variation contributes to the risk of relapse and to the risk of short- and long-term serious adverse effects of therapy. Our goal is to identify the inherited genomic variants that contribute to interindividual differences in response in patients with ALL. We discuss results of whole-genome interrogations of germline DNA in ALL.
儿童急性淋巴细胞白血病（ALL）为药物基因组学研究提供了一个杰出的模型：它是一种对药物有反应的播散性癌症，约85%的患者仅通过药物就能治愈，但某些亚组的复发率仍然高得令人无法接受。遗传基因组变异会导致复发风险以及治疗的短期和长期严重不良反应风险。我们的目标是识别导致ALL患者个体反应差异的遗传基因组变异。我们讨论了ALL患者种系DNA全基因组检测的结果。
